{"id":475515,"date":"2021-04-13T08:47:43","date_gmt":"2021-04-13T12:47:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/"},"modified":"2021-04-13T08:47:43","modified_gmt":"2021-04-13T12:47:43","slug":"orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/","title":{"rendered":"Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">RARITAN, N.J.<\/span>, <span class=\"xn-chron\">April 13, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=1337697035&amp;u=https%3A%2F%2Fwww.orthoclinicaldiagnostics.com%2Fen-us%2Fhome%2F&amp;a=Ortho+Clinical+Diagnostics\" rel=\"nofollow noopener\">Ortho Clinical Diagnostics<\/a>\u00a0(Nasdaq: OCDX),\u00a0one of the world&#8217;s largest pure-play in vitro diagnostics companies,\u00a0today announced it received CE Marking for its VITROS\u00ae SARS-CoV-2 Antigen Test, initially launched in October 2020.\u00a0The CE Mark allows for more convenient sample collection and expanded viral transport media. <\/p>\n<p>&#8220;Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these &#8216;back-to-normal&#8217; measures,&#8221; said <span class=\"xn-person\">Chockalingam Palaniappan<\/span>, PhD, chief innovation officer, Ortho Clinical Diagnostics. &#8220;Ortho&#8217;s customers continue to trust its COVID-19 testing solutions\u2014including the updated antigen test\u2014to efficiently meet the demand for accurate mass testing and fast, trusted results.&#8221;<\/p>\n<p>\n        <b>Updates to Ortho&#8217;s COVID-19 antigen test include:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b><br \/>\n            <i>More Convenient Sample Collection<br \/><\/i><br \/>\n          <\/b>When utilizing Ortho&#8217;s antigen test, personnel at hospitals, reference labs, and other healthcare settings will now be able to use a nasal sample which is more convenient than the nasopharyngeal swab specimen collection method. <\/li>\n<li>\n          <b><br \/>\n            <i>Additional Viral Transport Media (VTM)<br \/><\/i><br \/>\n          <\/b>Laboratories will now be able to utilize three additional viral transport media (VTM) options. Designed to preserve the integrity of collected samples during transportation to laboratories, new VTM options authorized for use with the VITROS\u00ae SARS-CoV-2 Antigen Test include Saline, which is readily available and cost effective, or Phosphate Buffered Saline (PBS), Bartels FlexTrans\u2122 transport media [Trinity Biotech], and the World Health Organization&#8217;s formulation of VTM, in addition to the existing CDC&#8217;s formulation of VTM, COPAN Universal Transport Media (UTM)\u00ae, and Hardy R99 VTM\u2014expanding options and testing capacity for customers who use Ortho&#8217;s antigen assay. <\/li>\n<li>\n          <b><br \/>\n            <i>New Sensitivity Data<br \/><\/i><br \/>\n          <\/b>The VITROS\u00ae SARS-CoV-2 Antigen Test now demonstrates 98 and 92.3 percent sensitivity (nasopharyngeal and nasal, respectively) for samples with a PCR cycle threshold (Ct\u2014 an assessment of viral load), of less than 30. Studies <sup>1,2<\/sup> have shown that samples with PCR CT values at 30 &#8211; 33 or greater carry little to no live virus, suggesting these patients may no longer be infectious. This further solidifies the test&#8217;s clinical utility in identifying individuals who are in the acute stage of COVID-19 infection when the risk for viral transmission is the highest.<\/li>\n<\/ul>\n<p>\n        <b>About the VITROS\u00ae SARS-CoV-2 Antigen Test\u00a0<\/b>\n      <\/p>\n<p>Initially CE Marked in <span class=\"xn-chron\">October 2020<\/span>, Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test offers reliable detection of SARS-CoV-2 in patients suspected of COVID-19 by their\u00a0healthcare provider within seven days of the onset of symptoms\u00a0with high sensitivity and specificity. With utility for mass-scale testing and same-day results for labs, Ortho&#8217;s antigen test can be processed at a rate of up to 130 tests per hour on a single analyzer, bolstering the ability of hospitals and reference labs to address testing backlogs, supply shortages, and delayed results that have undermined previous testing efforts. The VITROS\u00ae SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.\u00a0<\/p>\n<p>\n        <b>About Ortho&#8217;s VITROS<sup>\u00ae<\/sup> COVID-19 Testing Solutions<\/b>\n      <\/p>\n<p>Ortho&#8217;s SARS-CoV-2 Antigen Test is the latest addition to the company&#8217;s <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=4209148421&amp;u=https%3A%2F%2Fwww.orthoclinicaldiagnostics.com%2Fglobal%2Fcovid19%2F&amp;a=COVID-19+solutions%2C+which+include+two+COVID-19+antibody+tests+%E2%80%94+Total+and+IgG\" rel=\"nofollow noopener\">COVID-19 solutions, which include two COVID-19 antibody tests \u2014 Total and IgG<\/a> \u2014 both of which have U.S. Food and Drug Administration (FDA) Emergency Use Authorization and CE Mark. <\/p>\n<p>Because Ortho&#8217;s VITROS Systems are already installed worldwide, reporting times may be further improved because lab staff require no additional training, and the instruments are already connected to existing laboratory information systems and software. These systems are self-contained and do not require an external water source to run.<\/p>\n<p>Questions from laboratories, health care providers, or government officials regarding Ortho&#8217;s COVID-19 solutions can be directed to: <a target=\"_blank\" href=\"mailto:OrthoCOVID19Test@orthoclinicaldiagnostics.com\" rel=\"nofollow noopener\">OrthoCOVID19Test@orthoclinicaldiagnostics.com<\/a><u>.<\/u>\u00a0For more information visit: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=4078630954&amp;u=https%3A%2F%2Fwww.orthoclinicaldiagnostics.com%2Fglobal%2Fcovid19%2F&amp;a=https%3A%2F%2Fwww.orthoclinicaldiagnostics.com%2Fglobal%2Fcovid19%2F\" rel=\"nofollow noopener\">https:\/\/www.orthoclinicaldiagnostics.com\/global\/covid19\/<\/a>.\u00a0<\/p>\n<p>\n        <b>About Ortho Clinical Diagnostics<\/b>\n      <\/p>\n<p>Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world&#8217;s largest pure-play in vitro diagnostics (IVD) companies.<\/p>\n<p>More than 800,000 patients across the world are impacted by Ortho&#8217;s tests each day.\u00a0<i>Because Every Test is a Life<span>\u2122<\/span><\/i>, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho&#8217;s customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.<\/p>\n<p>From launching the first product to determine Rh+ or Rh- blood type, developing the world&#8217;s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. <\/p>\n<p>The company is powered by <span class=\"xn-person\">Ortho Care<\/span><span>\u2122<\/span>, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe.\u00a0\u00a0<\/p>\n<p>For more information, visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=1283189485&amp;u=http%3A%2F%2Fwww.orthoclinicaldiagnostics.com%2F&amp;a=Ortho%27s+website%C2%A0\" rel=\"nofollow noopener\">Ortho&#8217;s website\u00a0<\/a>or social media channels: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=3602049821&amp;u=https%3A%2F%2Fnam11.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fortho-clinical-diagnostics%26data%3D04%7C01%7Celaine.colon%40orthoclinicaldiagnostics.com%7Cd797453839894256df1f08d8d4eb1751%7C6e63ffc0c2fc4cc4b6c4666b2ce89d92%7C0%7C0%7C637493453465851706%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3DgT69nWBCtC6mKpfMYOCKA4gpiq2SFt%252BISqGXqiqz%252BKM%253D%26reserved%3D0&amp;a=LinkedIn\" rel=\"nofollow noopener\">LinkedIn<\/a>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=3073102313&amp;u=https%3A%2F%2Fnam11.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Ftwitter.com%252Forthoclinicaldx%253Flang%253Den%26data%3D04%7C01%7Celaine.colon%40orthoclinicaldiagnostics.com%7Cd797453839894256df1f08d8d4eb1751%7C6e63ffc0c2fc4cc4b6c4666b2ce89d92%7C0%7C0%7C637493453465861699%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3Dk9ojndQcPacZd7w6VdoYBofxhAn9sdislKn0R7tx9WY%253D%26reserved%3D0&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a>, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=2891472224&amp;u=https%3A%2F%2Fnam11.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.facebook.com%252FOrthoClinicalDX%252F%26data%3D04%7C01%7Celaine.colon%40orthoclinicaldiagnostics.com%7Cd797453839894256df1f08d8d4eb1751%7C6e63ffc0c2fc4cc4b6c4666b2ce89d92%7C0%7C0%7C637493453465871694%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3DoQqcJmUhIvF03Xw9gK%252FeoKagz73yNb4Oi4NHlwsQ8Mg%253D%26reserved%3D0&amp;a=Facebook\" rel=\"nofollow noopener\">Facebook<\/a>\u00a0and\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=2831780437&amp;u=https%3A%2F%2Fnam11.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.youtube.com%252Fchannel%252FUCWH7q_2wI_25OjHS3fcci8g%26data%3D04%7C01%7Celaine.colon%40orthoclinicaldiagnostics.com%7Cd797453839894256df1f08d8d4eb1751%7C6e63ffc0c2fc4cc4b6c4666b2ce89d92%7C0%7C0%7C637493453465871694%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3DpMFaa9%252F4k%252FKKLPPF4ETFVJiLUgEK%252FCxn9xy5Ebb9Zjc%253D%26reserved%3D0&amp;a=YouTube\" rel=\"nofollow noopener\">YouTube<\/a>.\u00a0<\/p>\n<p>\n        <sup>1<\/sup>\u00a0Viral cultures for COVID-19 infectivity assessment. Systematic review. <span class=\"xn-person\">Tom Jefferson<\/span>, <span class=\"xn-person\">Elizabeth Spencer<\/span>, <span class=\"xn-person\">Jon Brassey<\/span>, <span class=\"xn-person\">Carl Heneghan<\/span>. medRxiv 2020.08.04.20167932; doi: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3117819-1&amp;h=1796127201&amp;u=https%3A%2F%2Fdoi.org%2F10.1101%2F2020.08.04.20167932&amp;a=https%3A%2F%2Fdoi.org%2F10.1101%2F2020.08.04.20167932\" rel=\"nofollow noopener\">https:\/\/doi.org\/10.1101\/2020.08.04.20167932<\/a>.\u00a0 <\/p>\n<p>\n        <sup>2<\/sup>\u00a0N Engl J Med 2020;382:2081-90. DOI: 10.1056\/NEJMoa2008457\u00a0 <\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media-301267688.html\">http:\/\/www.prnewswire.com\/news-releases\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media-301267688.html<\/a><\/p>\n<p>SOURCE  Ortho Clinical Diagnostics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY31070&amp;Transmission_Id=202104130844PR_NEWS_USPR_____NY31070&amp;DateId=20210413\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire RARITAN, N.J., April 13, 2021 \/PRNewswire\/ &#8212;\u00a0Ortho Clinical Diagnostics\u00a0(Nasdaq: OCDX),\u00a0one of the world&#8217;s largest pure-play in vitro diagnostics companies,\u00a0today announced it received CE Marking for its VITROS\u00ae SARS-CoV-2 Antigen Test, initially launched in October 2020.\u00a0The CE Mark allows for more convenient sample collection and expanded viral transport media. &#8220;Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these &#8216;back-to-normal&#8217; measures,&#8221; said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. &#8220;Ortho&#8217;s customers continue to trust its COVID-19 testing solutions\u2014including the updated antigen test\u2014to efficiently meet the demand for accurate mass testing and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-475515","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ortho&#039;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ortho&#039;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire RARITAN, N.J., April 13, 2021 \/PRNewswire\/ &#8212;\u00a0Ortho Clinical Diagnostics\u00a0(Nasdaq: OCDX),\u00a0one of the world&#8217;s largest pure-play in vitro diagnostics companies,\u00a0today announced it received CE Marking for its VITROS\u00ae SARS-CoV-2 Antigen Test, initially launched in October 2020.\u00a0The CE Mark allows for more convenient sample collection and expanded viral transport media. &#8220;Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these &#8216;back-to-normal&#8217; measures,&#8221; said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. &#8220;Ortho&#8217;s customers continue to trust its COVID-19 testing solutions\u2014including the updated antigen test\u2014to efficiently meet the demand for accurate mass testing and &hellip; Continue reading &quot;Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-13T12:47:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media\",\"datePublished\":\"2021-04-13T12:47:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/\"},\"wordCount\":875,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY31070&amp;sd=2021-04-13\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/\",\"name\":\"Ortho's VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY31070&amp;sd=2021-04-13\",\"datePublished\":\"2021-04-13T12:47:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY31070&amp;sd=2021-04-13\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY31070&amp;sd=2021-04-13\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ortho's VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/","og_locale":"en_US","og_type":"article","og_title":"Ortho's VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media - Market Newsdesk","og_description":"PR Newswire RARITAN, N.J., April 13, 2021 \/PRNewswire\/ &#8212;\u00a0Ortho Clinical Diagnostics\u00a0(Nasdaq: OCDX),\u00a0one of the world&#8217;s largest pure-play in vitro diagnostics companies,\u00a0today announced it received CE Marking for its VITROS\u00ae SARS-CoV-2 Antigen Test, initially launched in October 2020.\u00a0The CE Mark allows for more convenient sample collection and expanded viral transport media. &#8220;Regions across the world are in various stages of reopening and recovering, yet there remains a great need for reliable tests that can be performed quickly and in bulk to ensure the continued safety of these &#8216;back-to-normal&#8217; measures,&#8221; said Chockalingam Palaniappan, PhD, chief innovation officer, Ortho Clinical Diagnostics. &#8220;Ortho&#8217;s customers continue to trust its COVID-19 testing solutions\u2014including the updated antigen test\u2014to efficiently meet the demand for accurate mass testing and &hellip; Continue reading \"Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-13T12:47:43+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media","datePublished":"2021-04-13T12:47:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/"},"wordCount":875,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/","name":"Ortho's VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13","datePublished":"2021-04-13T12:47:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY31070&amp;sd=2021-04-13"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orthos-vitros-sars-cov-2-antigen-test-for-high-volume-covid-19-testing-receives-ce-mark-allows-for-more-convenient-sample-collection-and-expanded-viral-transport-media\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ortho&#8217;s VITROS\u00ae SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=475515"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475515\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=475515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=475515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=475515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}